NCAM1 and extranodal nasal NK/T cell lymphoma: Hence, we conducted a retrospective study in a large cohort of 443 patients, to identify if patients of CD56-negative NKTCL had a worse outcome than patients of CD56-positive NKTCL, especially who received chemotherapy with or without asparaginase-based regimens.